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Objective: We sought to evaluate the effectiveness of clinical staging of depth of
tumor invasion (cT), the relationship of cT to survival, the benefits of downstaging
cT, and the role of cT in treatment decisions.
Methods: The accuracy of determining T by means of endoscopic ultrasonography
and the relationship of cT to survival were assessed in 209 patients undergoing
esophagectomy alone for esophageal carcinoma. The benefit of downstaging cT was
assessed in 128 patients undergoing induction therapy and esophagectomy. The role
of cT in treatment decisions was determined by integrating these results with the
results of previous work.
Results: Compared with pathologic T (pT), cT was 87% accurate, 82% sensitive,
91% specific, 89% positively predictive, and 86% negatively predictive of tumors
confined to (T2) or invading beyond (T2) the esophageal wall. In cN0, increas-
ing cT was predictive of progressively poorer survival. For each category of pT N0,
cT accurately predicted survival, except for pT3, which was underestimated (P 
.0001). In cN0, downstaging by induction therapy was beneficial only if tumors
invaded beyond the wall (cT3, P  .0003). In cN1, it was beneficial only when
downstaging was synchronous in cT3/T4 (P  .001).
Conclusions: cT should be the principal determinant of treatment in cN0. In cN0, if
endoscopic ultrasonography identifies tumors of greater than cT2, multimodality
therapy should be considered. However, only when cT3/T4 tumors are downstaged
to pT2 or less will patients benefit, but their survival will not equal that of patients
with tumors of cT2 or less having esophagectomy alone. If endoscopic ultrasonog-
raphy identifies tumors of cT2 or less, esophagectomy alone should be used because
induction therapy might adversely affect survival.
The categorization of TNM staging of esophageal carcinoma reflectsdisease progression: increasing depth of invasion by the primarytumor (T) to regional lymph node metastases (N) to distant metas-tases (M). However, in treatment decisions the hierarchy of stagingcriteria is reversed. Discovery of distant metastases (M1) has dismalprognosis and generally renders patients inoperable1; discovery of
regional lymph node metastases (N1), with its grave prognosis, makes esophagec-
tomy alone ineffective, leading to a search for successful multimodality therapies.2
When esophagectomy was the only therapeutic option, accurate clinical deter-
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mination of the depth of tumor invasion (cT) was not
necessary because the pathologic depth of tumor invasion
(pT) provided all the information available for prognostica-
tion. Today, the complete spectrum of esophageal carci-
noma, from high-grade dysplagia to distant metastatic dis-
ease, is seen. Also, many therapeutic options are available.
Thus, in patients without distant or regional lymph node
metastases, treatment decisions must be made on the basis
of cT.
Therefore, the purposes of this study were to evaluate the
effectiveness of clinical staging of depth of tumor invasion
(cT), the relationship of cT to survival, the benefits of
downstaging cT, and the role of cT in treatment decisions.
Patients and Methods
Patients
Between 1983 and January 1, 2001, 646 patients with esophageal
carcinoma underwent esophagectomy at The Cleveland Clinic
Foundation. From this database, 337 patients were identified with
known clinical (before therapy) and pathologic T, N, and M status
(Table 1).3
Staging
Before treatment, clinical depth of tumor invasion (cT) and clinical
regional lymph node status (cN) were determined by endoscopic
esophageal ultrasonography (EUS) according to the 1997 Ameri-
can Joint Committee on Cancer criteria (Table 2).3 EUS definition
of T focused on the fourth ultrasonographic layer to define cT1 to
cT3 (Figure 1). cT4 was defined by EUS evidence for invasion of
adjacent structures. In these patients EUS and computed tomo-
graphic scanning staged all but 7 patients as having cM0 disease.
After esophagectomy, the pathologic depth of tumor invasion
(pT) and pathologic regional lymph node status (pN) were deter-
mined (Table 2). The pT categories were p high-grade dysplasia if
malignant cells were confined to the epithelium and did not breach
the basement membrane, pT1 if the tumor did not invade beyond
the submucosa, pT2 if the tumor invaded the muscularis propria
but not beyond, pT3 if the tumor invaded the periesophageal
tissue, and pT4 if the tumor invaded adjacent structures (Figure
1).3 If no residual tumor was found after induction therapy, the
patient’s status was pT0. At resection, all accessible distant sites
were evaluated. Twenty-five patients had pM1a (7%) tumors, and
10 had pM1b (3%) tumors.
Treatment
Of the 337 patients, 209 underwent esophagectomy alone (Table
1). Because this group of patients underwent esophagectomy im-
mediately after clinical staging with no intervening therapies, this
provided information about the effectiveness of clinical staging of
T in terms of referent values (accuracy, sensitivity, specificity,
positive predictive value, and negative predictive value). It also
provided survival data after esophagectomy alone in relation to cT.
The remaining 128 patients received induction therapy after
clinical staging and before esophagectomy (Table 1). This group
TABLE 1. Patient characteristics
Characteristic
Treatment
P value
Total Esophagectomy alone Induction therapy
n % of 337 n % of 209 n % of 128
Demography
Male 280 83 174 83 106 83 .9
White 319 95 202 97 117 91 .04
Age (mean  SD) 62  10 63  11 60  9 .002
Age range (26-84) (33-84) (26-77)
Tumor .030
Adenocarcinoma 272 81 178 85 94 73
Squamous 61 18 29 14 32 25
Adenosquamous 4 1 2 1 2 2
Differentiation .01
Poor and moderately poor 182 54 101 48 81 63
Moderate 85 25 55 26 30 23
Well and moderately well 70 21 53 25 17 13
Surgical approach .001
Thoracotomy 267 79 143 68 124 97
Transhiatal 69 21 65 31 4 3
Laparotomy 1 0.3 1 0.5 0 0
Surgical margins .2
Positive 23 7 17 8 6 5
No. of N1 nodes .3
0 181 54 107 51 74 58
1 32 10 18 9 14 11
2 25 7 15 7 10 8
3 or more 99 29 69 33 30 23
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provided no information about referent values; rather, it provided
information relevant to the benefit and role of downstaging T.
Esophagectomy alone. Of the 209 patients undergoing esoph-
agectomy alone, 68% had resection with 2-field lymphadenectomy
by means of thoracotomy. Thirty-one percent had transhiatal
esophagectomy with lymph node sampling (Table 1). R0 resec-
tions were achieved in 92%.
Induction therapy and esophagectomy. Of the 128 patients
receiving induction therapy, 16 patients before 1991 received
preoperative chemotherapy only; this included 2 planned courses
of cisplatin, etoposide, and doxorubicin.4 Since 1991, patients
were offered induction chemoradiotherapy for cN1 and cT3 or cT4
cancers. However, treating physicians had the latitude to treat
patients with cT1 N0 (n  3) and cT2 N0 (n  8) cancers with
induction therapy. Induction therapy included 2 courses of chemo-
therapy, either cisplatin and 5-fluorouracil5 or cisplatin and taxol.6
Concurrent with chemotherapy, accelerated fractionation radiation
therapy (1.5 Gy twice daily to a total dose of 45 Gy) was admin-
istered in a split fashion over 41⁄2 weeks. Esophagectomy was
performed 4 to 6 weeks later. Ninety-seven percent of patients had
esophagectomy with 2-field lymphadenectomy via thoracotomy,
and 3% had transhiatal esophagectomy with lymph node sampling
(Table 1). R0 resections were achieved in 95% of patients.
These treatment protocols had approval and were reviewed
annually by The Cleveland Clinic Foundation’s Institutional Re-
view Board. Written informed consent was obtained from all
patients before treatment began.
Study End Point and Patient Follow-up
The end point of the study was all-cause mortality. Patients were
followed by means of periodic clinic visits and cross-sectional
systematic follow-up in February 2001. At that time, 2 patients
previously followed for 2.8 and 7.8 years, respectively, could not
be located. A search of the Social Security Death Index did not find
the Social Security numbers deactivated; it was therefore assumed
that the patients were alive 6 months before February 2001 (Sep-
tember 1, 2000). Mean follow-up was 26  15 months (43  35
months in patients alive at last follow-up).
Data Analysis
Descriptive. Descriptive statistics are summarized as means
and SDs for continuous variables and as frequencies and percent-
ages for categorical variables.
Effectiveness of clinical staging of T. cT was compared with
pT in the group undergoing esophagectomy alone (n  209). For
this comparison, clinical and pathologic T stages were grouped as
follows: (1) T2 or less, T2, and greater than T2 and (2) T2 or less
and greater than T2.
Conventional diagnostic characterization is in terms of the
dichotomy of “positivity” and “negativity.” Because cT is a graded
variable, positivity and negativity had to be defined for each tumor
depth. In this comparison positivity meant patients had the pT
stage being considered, and negativity meant patients did not have
the pT stage being considered (either lower or higher pT). True
positivity meant patients with the pT stage being considered were
TABLE 2. Staging
Characteristic
Treatment
P value
Total Esophagectomy alone Induction therapy
n % of 337 n % of 209 n % of 128
Clinical stage
cT .001
HGD 27 8 27 13 0 0
1 24 7 20 10 4 3
2 61 18 43 21 18 14
3 216 64 112 54 104 81
4 9 3 7 3 2 2
cN .001
0 151 45 111 53 40 31
1 186 55 98 47 88 69
Pathologic stage
pT .001
0 23 7 0 0 23 18
HGD 25 7 21 10 4 3
1 80 24 59 28 21 16
2 38 11 17 8 21 16
3 165 49 109 52 56 44
4 6 2 3 1 3 2
pN .2
0 181 54 107 51 74 58
1 156 46 102 49 54 42
pM .17
0 302 90 189 90 113 88
1a 25 7 12 6 13 10
1b 10 3 8 4 2 2
HGD, High-grade dysplasia.
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correctly clinically staged. False positivity meant patients without
the pT stage being considered were incorrectly clinically staged.
True negativity meant patients without the pT stage being consid-
ered were correctly clinically staged. False negativity meant pa-
tients with the pT stage being considered were incorrectly clini-
cally staged. Thus, sensitivity was defined as true-positives divided
by the sum of true-positives and false-negatives, specificity as
true-negatives divided by the sum of true-negatives and false-
positives, predictive value of a positive test as true-positives di-
vided by the sum of true-positives and false-positives, predictive
value of a negative test as true-negatives divided by the sum of
true-negatives and false-negatives, and accuracy of staging T as
the sum of true-positives and true-negatives divided by the total
number of patients undergoing esophagectomy alone.
Relationship of cT to survival. Prognostication by clinical
staging was evaluated by survival analysis of the group undergoing
esophagectomy alone (n  209). Nonparametric estimates of sur-
vival were obtained by the Kaplan-Meier method. A parametric
method was used to resolve the number of phases of instantaneous
risk of death (hazard function) and to estimate their shaping
parameters.7 Estimates of survival were considered reliable to 10
years. Multivariable analysis of survival in this group was neces-
sary to demonstrate the prognostic value of clinical staging com-
pared with pathologic staging and to provide a risk-adjusted com-
parison with induction therapy.
For multivariable analyses, only variables known before esoph-
agectomy and the planned surgical approach were examined. Vari-
ables included demography (Table 1), depth of tumor invasion by
EUS (cT), preoperative assessment of mediastinal nodes (cN),
planned surgical approach (Table 1), and date of operation. Depth
of tumor invasion was analyzed both as an ordinal variable and as
a set of dichotomous variables for each cT level; these produced
equivalent models. Two-way interactions of all variables with cN
and surgical approach and 3-way interactions with cN, surgical
approach, and the other variables were examined.
Continuous and ordinal variables were assessed univariably by
decile risk analysis to suggest transformations of scale required to
ensure that relationships of these measured variables were well
calibrated to model outcome.
Multivariable analysis was performed simultaneously for 2
hazard phases identified from the data. Both a guided technique of
entry of variables into the multivariable models8 and bootstrap
bagging with 1000 resamplings were used.9 A P value of .1 for
retention of variables in final models was used.
Patients with pN0 M0 tumors undergoing esophagectomy alone
were studied to evaluate the relationship of cT to pT in terms of
prognostication. For each patient, a survival curve was predicted
on the basis of cTN from the multivariable equation. For each
category of pT, these survival curves based on cT were averaged
and compared with the actual Kaplan-Meier estimates.10 To test
Figure 1. The esophageal wall is visualized as 5 alternating layers of differing echogenicity by means of EUS. The
fourth ultrasonographic layer is critical to differentiating T1, T2, and T3 carcinomas. Left and middle, The first
(inner) layer is hyperechoic (white) and represents the superficial mucosa (epithelium and lamina propria). The
second layer is hypoechoic (black) and represents the deep mucosa (muscularis mucosae). The third layer is
hyperechoic and represents the submucosa. The fourth layer is hypoechoic and represents the muscularis propria.
The fifth layer is hyperechoic and represents the periesophageal tissue. Right, T1 carcinoma: no invasion beyond
the submucosa. The tumor is confined to the first 3 ultrasonographic layers. It does not involve the fourth
ultrasonographic layer. T2 carcinoma: invasion into but not beyond the muscularis propria. The tumor is confined
to the fourth ultrasonographic layer. T3 carcinoma: invasion into the periesophageal tissue. The tumor breaches
the fourth ultrasonographic layer.
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for differences between expected and observed survival, cumula-
tive hazard at the time of each patient’s follow-up (or death) was
calculated from this multivariable equation. The sum of the cumu-
lative hazard values was the number of expected deaths on the
basis of cT. A 2 goodness-of-fit test was used to compare the
number of expected and observed deaths.10
Benefit of downstaging cT. The benefits of downstaging cT by
induction therapy were derived from survival analysis. Methods of
survival analysis within the induction therapy group (n  128),
including multivariable analysis, mirrored those for the group
undergoing esophagectomy alone (see above).
To evaluate the benefit of downstaging cT, we compared actual
survival of these patients with predicted survival had they under-
gone esophagectomy alone. For each patient, a survival curve was
predicted on the basis of cTN from the multivariable equation of
esophagectomy alone. For selected categories of cT and pT, these
survival curves were averaged and compared with the actual
Kaplan-Meier estimates and tested for differences between ex-
pected and observed survival as described above.10
cT and treatment decisions. The benefit of staging T and the
use of induction therapy to downstage T were integrated with the
results of our study on staging and downstaging N1 tumors.2 A
multivariable analysis of survival in patients undergoing induction
therapy was performed to assess the independent benefit of down-
staging T. Unlike the analyses above, this analysis included patho-
logic stage and number and percentage of positive nodes (Tables 1
and 2). In addition, variables were formed for the differences
between cN and pN and between cT and pT, their interactions with
cN and pN, and interactions with surgical approach.
Results
Effectiveness of Clinical Staging of T
Among 209 patients undergoing esophagectomy alone, clin-
ical staging was 81% to 87% accurate, 82% to 99% specific,
and 79% to 96% negatively predictive (Table 3). For tumors
of T2 or less, EUS had low sensitivity (58% and 59%). It
also poorly staged T2 tumors (positive predictive value of
only 23%). However, in the clinically important distinction
of tumors confined to the esophageal wall (T2) from those
invading beyond (T2), clinical staging by means of EUS
was 87% accurate, 82% sensitive, 91% specific, 89% pos-
itively predictive, and 86% negatively predictive.
Relation of cT to Survival
Increasing cT was predictive of progressively poorer sur-
vival in patients with cN0 disease after esophagectomy
alone by both nonparametric and parametric analyses (Fig-
ure 2). In addition to cT, cN1, thoracotomy, and older age
were risk factors for mortality after esophagectomy alone
(Table 4).
For patients with pN0 M0 tumors undergoing esopha-
gectomy alone, the equation (Table 4) based on cT accu-
rately predicted survival (P  .15, Figure 3), except for
pT3, which was underestimated (P  .0001). In this group
20.6 deaths were predicted, but only 13 were observed. The
excess deaths were predicted in the subgroup of patients
with pT3 N0 M0 tumors who were understaged (ie, patients
in whom N1 nodes had been predicted by EUS [cN1] but
who had no regional lymph node metastases at operation).
Benefit of Downstaging cT
Compared with esophagectomy alone, the benefit of down-
staging cT by induction therapy was evident only in patients
with cT3 N0 M0 tumors (Figure 4). In the first 2 years,
observed and expected survival was similar; however, after
that, patients receiving induction therapy had improved
survival. Of the 28 patients with cT3 N0 tumors receiving
induction therapy, 12 died. Twenty-five deaths were pre-
dicted had the patients undergone esophagectomy alone
(P  .0001). This illustrates that in cN0 tumors invading
beyond the esophageal wall, induction therapy provides a
survival advantage that is realized after 2 years.
In contrast, harm of induction therapy in patients with
cT1 N0 and cT2 N0 tumors is shown in Figure 5. Of 11
patients who underwent induction therapy, 10 died: ie, 7 of
cancer, 2 of late treatment toxicity, and 1 of unknown cause.
Only 1 patient is alive 91 months after treatment. Two
deaths were expected within the range of follow-up had
these patients undergone esophagectomy alone (P .0001).
The less-than-hoped-for benefit of complete sterilization
of cN1 tumors (pT0 N0) is shown in Figure 6. Patients
experienced an intermediate level of survival, possibly bet-
ter than expected (P  .07). Survival was similar for pa-
tients with cN0 (n  8) and cN1 (n  14) tumors who
experienced sterilization (pT0 N0, P  .5). Of 22 patients,
10 died: ie, 4 of cancer, 4 of treatment toxicity, and 2 of
causes unrelated to cancer.
TABLE 3. Accuracy of clinical staging of T for 209 patients undergoing esophagectomy alone
cT
pT Accuracy
(%)
Sensitivity
(%)
Specificity
(%)
PPV
(%)
NPV
(%)<pT2 pT2 >pT2
cT2 46 0 1 83 58 99 98 79
cT2 24 10 9 81 59 83 23 96
cT2 10 7 102 87 91 82 86 89
NPV, Negative predictive value; PPV, positive predictive value.
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cT and Treatment Decisions
Risk factors for death after induction therapy included older
age, female, increasing number of positive nodes, and less
downstaging of cT (Table 5). Figure 7 shows that there must
be synchronous downstaging of both cT and cN to improve
survival (Appendix 1). Patients with cN1 tumors who
downstaged to pN0 but still had tumor invasion beyond the
esophageal wall (pT3) had poor survival despite induction
therapy and esophagectomy. If there is synchronous down-
staging of cT and cN, there is a homogenization of survival
(Figure 7).
Discussion
Context
Tumor progression, and therefore TNM staging, is focused
on primary tumor (T), then regional nodes (N), and, finally,
distant sites (M). Prognosis is determined in reverse order of
this progression. Because T is the easiest to assess nonin-
vasively, it has become the focus of attention in clinical
staging. The impetus for this study was to determine when
clinical depth of tumor invasion (cT) was of importance in
making decisions in the treatment of esophageal carcinoma.
When palliation with single-modality therapy was the
aim of treatment, there was no need for clinical staging.
Clinical staging has become important since the introduc-
tion and increasing use of multimodality therapy. The effect
of treatment decisions in neoadjuvant therapy, made on the
basis of clinical staging, is difficult to assess because ther-
apy might downstage tumors or there might be disease
progression during therapy. In addition, the ability to clin-
ically stage the tumor after neoadjuvant therapy might be
TABLE 4. Risk factors for mortality after esophagectomy for patients undergoing esophagectomy alone (n  209)
Incremental risk factor
Hazard phase
Early Late
Coefficient  SD P value Coefficient  SD P value
Demography
Older age — — 0.62  0.189 .001
Tumor characteristics
cN1 10.7 .001 1.65  0.63 .01
Increasing cT — — 0.92  0.20 .0001
cT4 1.54  0.59 .009 — —
Planned surgery
Thoracotomy — — 1.24  0.40 .002
Figure 2. Survival after esophagectomy alone for cN0 esophageal cancer stratified according to cT. Symbols
represent Kaplan-Meier estimates for each clinically determined depth of tumor invasion and are accompanied by
vertical bars representing asymmetric 68% confidence limits of these estimates (equivalent to1 SE). The numbers
in parentheses represent survivors. The smooth curves are parametric estimates of survival for each clinical stage.
HGD, High-grade dysplasia.
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lost.11 Therefore, it is crucial to have effective and accurate
clinical staging and a clear relationship of staging to prog-
nosis to assess the benefit of current treatment and to direct
future treatment decisions.
Effectiveness of Clinical Staging of T
There is a misconception that accuracy of cT determination
by EUS increases incrementally with deeper tumor penetra-
tion.12 In a meta-analysis the reported accuracy was 84% for
Figure 4. Observed and predicted survival in patients with cT3 N0 tumors receiving induction therapy. Open circles
represent Kaplan-Meier estimates of observed survival. Vertical bars represent asymmetric 68% confidence limits
of these estimates (equivalent to 1 SE). Numbers in parentheses represent number of patients traced beyond that
point. The dashed line represents survivors beyond the last death recorded. The smooth curve enclosed by its
confidence limits is predicted survival had patients undergone esophagectomy alone (Table 4).
Figure 3. Survival after esophagectomy alone for pN0 M0 esophageal cancer stratified on the basis of pT. Symbols
represent Kaplan-Meier estimates for each pathologic depth of tumor invasion (pT). Fine dashed lines represent
survivors beyond the last recorded death. Solid curves represent survival for each pathologic depth of tumor
invasion predicted from the multivariable analysis (Table 4) based on clinical depth of tumor invasion (cT). HGD,
High-grade dysplasia.
Rice et al General Thoracic Surgery
The Journal of Thoracic and Cardiovascular Surgery ● Volume 125, Number 5 1097
G
TS
T1, 73% for T2, 89% for T3, and 89% for T4 tumors.13 A
review of the literature shows variation in accuracy with T:
75% to 82% for T1, 64% to 85% for T2, 89% to 94% for T3,
and 88% to 100% for T4 tumors.14 The least reliable of EUS
cT determinations is cT2.15 Except for T2 tumors, EUS
accuracy increases with increasing T.
In this study the determination of T by EUS was accu-
rate, specific, and negatively predictive. For tumors invad-
ing beyond the esophageal wall (T2), EUS was also
sensitive and positively predictive. However, EUS sensitiv-
ity in screening for less than T2 and T2 esophageal tumors
was poor because of high false negativity. The positive
predictive value of EUS determination of T2 was also poor
because of high false positivity.
The interplay of staging criteria and EUS anatomy par-
tially accounts for the problem with T2. The muscularis
propria is critical in differentiating T1, T2, and T3 tumors.
Tumors are defined as T1 if there is no invasion of the
muscularis propria, T2 if invasion is into the muscularis
propria, and T3 if invasion is beyond the muscularis propria.
For clinical evaluation, the fourth ultrasonographic layer is
interpreted as the muscularis propria. However, studies have
Figure 6. Observed and predicted survival in patients with cN1 tumors with any cT receiving induction therapy who
were found at operation to have a sterilized tumor (pT0 N0). The format is similar to that of Figure 4.
Figure 5. Observed and predicted survival in patients with cT1 N0 and cT2 N0 tumors receiving induction therapy.
The format is the same as for Figure 2, except Kaplan-Meier estimates are shown as filled circles.
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demonstrated that the third ultrasonographic layer is the
submucosa and the acoustic interface between the submu-
cosa and muscularis propria. The fourth ultrasonographic
layer is the muscularis propria minus the acoustic interface
between the submucosa and the muscularis propria.16,17
Therefore, the boundary necessary to completely differen-
tiate T2 from T3 tumors is contained in the third ultrasono-
graphic layer. Because 2 boundaries must be evaluated in
the determination of T2 and errors might occur at each, the
inaccuracy is potentially double that of T1 and T3 tumors.
However, for the clinically pertinent distinction of tu-
mors confined to the esophageal wall (T2) from those
invading beyond (T2) the esophageal wall, EUS is highly
accurate, specific, sensitive, positively predictive, and neg-
atively predictive.
Relationship of cT to Survival
Clinical staging of T is prognostic. Clinical staging of
tumors confined to the esophageal wall (cT2) and patho-
logic staging of these same tumors are similarly predictive
of prognosis. Clinical staging of tumors invading beyond
the esophageal wall (cT2) underestimates survival com-
pared with pathologic staging. The interplay of T and N in
these locally advanced tumors accounts for this underesti-
mation of survival. The majority of patients (80%) with
tumors invading beyond the esophageal wall (T2) will
have regional lymph node metastases.18 However, in the
minority without regional lymph node metastases (pN0),
clinical overstaging of regional lymph node status (cN1),
not inaccuracy in predicting depth of tumor invasion
(cT2) accounts for the underestimation of survival.
Figure 7. Kaplan-Meier estimates of survival in patients with cN1 tumors after induction therapy resulting in pN0
disease, according to residual pathologic depth of tumor invasion (pT). Fifteen cN1 patients had pT0 disease, 2 had
p high-grade dysplasia (pHGD) and 12 pT1 disease, 8 had pT2 disease, 9 had pT3 disease, and 1 had pT4 disease.
Kaplan-Meier estimates are depicted as in Figure 4.
TABLE 5. Incremental risk factors for mortality after esophagectomy in patients who received induction therapy (n  128)
Incremental risk factor
Hazard phase
Early Late
Coefficient  SD P value Coefficient  SD P value
Demography
Older age* 2.8  1.12 .02 — —
Female — — 1.46  0.69 .03
Tumor characteristics
No. of positive nodes† — — 5.3  2.0 .009
Change in T if patient had pN0 disease‡ — — 4.1  1.64 .01
*[50/age] inverse transformation.
†[1/ (number of positive nodes 1)] inverse transformation.
‡See “Patients and Methods” section for expression.
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Benefit of Downstaging cT
For patients with cN0 tumors, survival was enhanced by
induction therapy only for those with tumors invading be-
yond the wall (cT2) who were downstaged. Induction
therapy might reduce survival for patients with cT2 N0 or
less tumors. For patients with cN1 tumors downstaged to
pN0 by induction therapy, survival was enhanced compared
with that in patients not receiving induction therapy or those
not downstaged by induction therapy.2 For tumorss invad-
ing beyond the wall (cT2), if there was downstaging of N
but not T or vice versa, the survival advantage of induction
therapy was lost.
cT and Treatment Decisions
Treatment decisions should be based on cT only in patients
with cN0 M0 tumors. Patients with esophageal carcinomas
that have not metastasized to regional lymph nodes (cN0) or
breached the esophageal wall (cT2) have good survival
when treated with esophagectomy alone. Every effort
should be made to stage patients clinically and to identify
those with esophageal carcinomas confined to the esopha-
geal wall (cT2 N0 M0) because they are the best surgical
candidates and might be harmed by aggressive multimodal-
ity therapy. Once tumors have spread beyond the esopha-
geal wall (cT2) or metastasized to regional (cN1) or
nonregional (cM1a) lymph nodes, survival is drastically
reduced. Only patients with advanced tumors whose disease
is downstaged to pT2 N0 or less with induction therapy will
benefit from this therapy.
Limitations
This study is a small, nonrandomized, single-institution,
prospective experience. There might have been inaccuracies
of clinical staging and treatment biases over time. Analysis
was made difficult by selection of induction therapy for
individual patients. Therefore, inferences from application
of information on surgical intervention alone to the induc-
tion therapy group are not as robust as they would be had
this been a randomized trial. In addition, patients in whom
induction therapy was used almost universally received a
thoracotomy, and this factor in itself adds risk to the treat-
ment program,19 only one component of which is induction
therapy.
We thank Diane Baisden for data collection and follow-up and
Mary Ann Meljac and Tess Knerik for manuscript preparation.
References
1. Christie NA, Rice TW, Goldblum JR, Adelstein DJ, Rybicki LA,
Blackstone EH. M1a/M1b esophageal carcinoma: surgical relevance.
J Thorac Cardiovasc Surg. 1999;118:900-7.
2. Rice TW, Blackstone EH, Adelstein DJ, Zuccaro G Jr, Vargo JJ,
Goldblum JR, et al. N1 esophageal carcinoma: the importance of
staging and downstaging. J Thorac Cardiovasc Surg. 2001;121:454-
64.
3. American Joint Committee on Cancer. AJCC cancer staging manual.
5th ed. Philadelphia: Lippincott-Raven; 1997. p. 65-8.
4. Rice TW, Boyce GA, Sivak MV Jr, Adelstein DJ, Kirby TJ. Esoph-
ageal carcinoma: esophageal ultrasound assessment of preoperative
chemotherapy. Ann Thorac Surg. 1992;53:972-7.
5. Adelstein DJ, Rice TW, Becker M, Larto MA, Kirby TJ, Koka A, et
al. Use of concurrent chemotherapy, accelerated fractionation radia-
tion, and surgery for patients with esophageal carcinoma. Cancer.
1997;80:1011-20.
6. Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, et
al. Does paclitaxel improve the chemoradiotherapy of locoregionally
advanced esophageal cancer? A nonrandomized comparison with
fluorouracil-based therapy. J Clin Oncol. 2000;18:2032-9.
7. Blackstone EH, Naftel DC, Turner ME Jr. The decomposition of
time-varying hazard into phases, each incorporating a separate stream
of concomitant information. J Am Stat Assoc. 1986;81:615-24.
8. Baskerville JC, Toogood JH. Guided regression modeling for predic-
tion and exploration of structure with many explanatory variables.
Technometrics. 1982;24:9-17.
9. Breiman L. Bagging predictors. Machine Learning. 1996;24:123-40.
10. Ferrazzi P, McGiffin DC, Kirklin JW, Blackstone EH, Bourge RC.
Have the results of mitral valve replacement improved? J Thorac
Cardiovasc Surg. 1986;92:186-97.
11. Zuccaro G Jr, Rice TW, Goldblum JR, Mendendorp SV, Becker ME,
Pimentel R, et al. Endoscopic ultrasound cannot determine suitability
for esophagectomy after aggressive chemoradiotherapy for esophageal
cancer. Am J Gastroenterol. 1999;94:906-12.
12. Buenaventure P, Luketich JD. Surgical staging of esophageal cancer.
Chest Surg Clin North Am. 2000;10:487-97.
13. Ro¨sch T. Endosonographic staging of esophageal cancer: a review of
literature results. Gastrointest Endosc Clin N Am. 1995;5:537-47.
14. Saunders HS, Wolfman NT, Ott DJ. Esophageal cancer. Radiologic
staging. Radiol Clin North Am. 1997;35:281-94.
15. Heidemann J, Schilling MK, Schmassmann A, Maurer CA, Buchler
MW. Accuracy of endoscopic ultrasonography in preoperative staging
of esophageal carcinoma. Dig Surg. 2000;17:219-24.
16. Kimmey MB, Martin RW, Haggitt RC, Wang KY, Franklin DW,
Silverstein FE. Histologic correlates of gastrointestinal ultrasound
images. Gastroenterology. 1989;96:433-41.
17. Bolondi L, Casenova P, Santi V, Caletti G, Barbara L, Labo G. The
sonographic appearance of the normal gastric wall: an in vivo study.
Ultrasound Med Biol. 1986;12:991-8.
18. Rice TW, Zuccaro G Jr, Adelstein DJ, Rybicki LA, Blackstone EH,
Goldblum JR. Esophageal carcinoma: depth of tumor invasion is
predictive of regional lymph node status. Ann Thorac Surg. 1998;65:
787-92.
19. Rice TW, Blackstone EH, Goldblum JR, DeCamp MM, Murthy SC,
Falk GW, et al. Superficial adenocarcinoma of the esophagus. J Tho-
rac Cardiovasc Surg. 2001;122:1077-90.
20. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York:
John Wiley & Sons; 1989. p. 216-38.
Appendix 1
Linkage of T and N After Induction Therapy
The linkage between T and N after induction therapy (n  126)
was assessed by comparing cT and cN with pT and pN.
Method of Assessing Linkage
High-grade dysplasia and cT1 groups were coalesced to facilitate the
analyses. Clinical stage was then numerically scored: 1 cT1 or less;
2 cT2; 3 cT3; and 4 cT4. A similar score was assigned to pT,
except that absence of disease (pT0) was scored as zero. Change in T
was obtained by subtracting the cT score from the pT score. There-
fore, a negative difference indicated pT was less than cT (downstag-
ing or overstaging), and a positive difference indicated pT was
greater than cT (disease progression or understaging).
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Change in T was analyzed both univariably and multivariably
with respect to sex, race, cT, pT, cN, pN, pM, cell type, tumor
differentiation, and surgical margin. Either the Wilcoxon rank sum
test (dichotomous variables) or the Kruskal-Wallis test (variables
with 2 categories) was used to assess the association of these
variables to change in T.
For multivariable analysis, change in T was analyzed as an
ordinal variable with 5 levels (3, 2, 1, 0, and 1).20 Partic-
ular attention was paid to 4 possible combinations of N: cN0/pN0,
cN1/pN0, cN1/pN1, and cN0/pN1. The assumption of proportional
odds was reasonable, and therefore multivariable ordinal logistic
regression was used, which produces a different intercept for each
level of change of T. Except for combinations of N, variables were
retained in the analysis whose P value was greater than .1.
Linkage of T and N
cT was greater than pT in 46% of patients (downstaged or over-
staged), cT was equal to pT in 47%, and cT was less than pT in 7%
(disease progression or understaged). The higher cT, the lower pT
was after induction therapy (pT-cT more negative, Appendix Table
1). The higher pT, the more likely the tumor had remained un-
changed or progressed (pT-cT more positive). The difference
between cT and pT was similar irrespective of whether there was
cN1 (P  1). However, if the patient had pN0 tumors after
induction therapy, the magnitude of T decrease was greater (1.4
for pN0 vs 0.1 for pN1). The magnitude of T decrease was
greatest in patients with pN0 tumors who had been downstaged
from cN1 (ie, downstaging of T and N were synchronous); patients
who had or who eventually developed pN1 tumors had, on aver-
age, no change in T. Although the numbers are small, it is sug-
gestive (P  .06) that if distant metastatic disease were present
(M1), induction therapy did not affect T. Patients with squamous
cell cancers were more likely than those with adenocarcinomas to
have T decrease with induction therapy. Multivariable analysis
(Appendix Table 2) confirms these observations from univariable
analysis and indicates the effect of these variables on the magni-
tude of change in T. Thus, the greater the depth of tumor invasion
(cT), the greater the downstaging of T. If pN1 tumors were found,
it was highly likely that there was no T downstaging. With less
certainty, the model predicted that T was downstaged in patients
with squamous cell cancer more than in patients with adenocarci-
noma. The analysis also suggested that linkage among the above
factors accounted for the downstaging of cN1 to pN0 (P .5 for any
additional information).
Appendix TABLE 1. Change in T for 128 patients undergoing induction therapy
Variable n Mean  SD Median Minimum Maximum P value
CT .002
cT1 4 0.5 0.6 0.5 0 1
cT2 18 0.2 1.1 0 2 2
cT3 104 1.0 1.2 0 3 1
cT4 2 2.5 0.7 2.5 3 2
pT .001
pT0 23 2.9 0.3 3 3 2
pHGD/pT1 25 1.7 0.7 2 3 0
pT2 21 0.6 0.7 1 2 1
pT3 56 0.1 0.3 0 0 1
pT4 3 1.3 0.6 1 1 2
cN 1
cN0 40 0.9 1.4 0 3 2
cN1 88 0.9 1.2 0 3 1
pN .001
pN0 74 1.4 1.3 2 3 2
pN1 54 0.1 0.7 0 3 1
Change in N (cN to pN) .001
cN1 to pN0 46 1.6 1.2 2 3 1
cN0 to pN0 28 1.2 1.5 1 3 2
cN1 to pN1 12 0.1 0.5 0 1 1
cN0 to pN1 42 0.1 0.7 0 3 1
pM .06
pM0 113 1.0 1.3 0 3 2
pM1 15 0.3 0.6 0 2 0
Cell type .002
AD/AS 96 0.7 1.2 0 3 2
SQ 32 1.5 1.3 2 3 1
Differentiation .03
Poor or moderately poor 81 0.7 1.2 0 3 2
Moderately 30 1.3 1.3 1.5 3 1
Moderately well or well 17 1.2 1.3 1 3 1
HGD, High-grade dysplasia; AD/AS, adenocarcinoma and adenosquamous cell carcinoma; SQ, squamous cell carcinoma.
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Discussion
Dr Joshua R. Sonett (Baltimore, Md). Dr Rice and colleagues
have in the past contributed significantly with regard to the staging,
treatment, and prognosis of esophageal carcinoma. This present
work continues to review their large patient population at The
Cleveland Clinic with critical analysis of the results of surgical and
multimodality treatment of esophageal cancer, as stratified on the
basis of pretreatment clinical staging. This continued emphasis on
the importance of pretreatment staging and resultant stage-specific
treatment paradigms cannot be underestimated. This article, as has
the group’s previous work, further establishes the clinical impor-
tance and utility of EUS, and pretreatment EUS might now be
considered the standard of care in the treatment of all patients with
esophageal cancer.
To a mere mortal physician, the statistics are, to say the least,
daunting in the article, and I will trust Dr Rice’s and Dr Blackstone’s
analysis of the variables. However, I do have several questions re-
garding the conclusions that were drawn from this analysis.
In the article a final conclusion is that patients with clinically
staged T1 or T2 N0 esophageal carcinoma might not benefit from
induction therapy and, in fact, might be harmed. However, as you
noted, the accuracy of staging T2 in the article was only 81%, with a
positive predictive value of only 23%. The analysis of all these
patients was also based on clinical staging rather than pathologic
staging of the lymph nodes, a method that might additionally misstage
20% of the patients. Thus, do you think that this potential 20% error
rate in accurately defining malignant lymph nodes and the inaccuracy
of defining true T2 carcinomas weaken your conclusions? Could your
conclusions and analysis be enhanced if the data were based on true
pathologic staging, as might be gained first by fine-needle EUS
analysis and then selective use of thoracoscopy or laparoscopy pa-
tients within clinically staged N0 disease? Can such a conclusion
really be drawn from a cohort of only 11 patients?
Another interesting correlation that you have identified was the
poor prognosis of those patients who continued to have N1 carci-
noma after induction therapy and those patients who continued to
have T3 carcinoma, N1 carcinoma, or both, either by progression
of disease or lack of response. The poor prognosis of patients with
residual malignant lymph nodes after induction therapy has also
been seen with non-small cell lung cancer after induction therapy.
Given these results, would you consider deferring surgical resec-
tion in those patients undergoing induction therapy in whom you
can prove either a lack of T downstaging or persistence of malig-
nant lymph nodes?
Finally, clearly T and N staging are related. As in most solid
tumors, as you have shown, an increasing T stage will result in a
higher percentage of patients with positive lymph nodes. However,
despite this linkage, the correlation is not linear, and significant
variability in the biologic activity and characteristics of tumors will
result in earlier and/or later lymphatic or systemic failure, or both.
Ultimately, molecular and biologic differences in tumor disease must
play a major role in the overall prognosis and TNM stage of any
tumor. Do you envision a staging system in the future that includes a
biologic modification for molecular and biologic parameters?
Dr Rice. Concerning why we did not use true pathologic stage,
we have to make decisions based on clinical stage. There is no
doubt that there is an improvement in stratification if pT is used.
Fine-needle aspiration is now the standard of care. If there is an
EUS-identified large node, the patient should undergo fine-needle
aspiration. However, this paper discusses depth of tumor invasion,
and in the analysis EUS is very good at identifying invasion beyond
the esophageal wall. Whenever we use EUS, we are looking for T3
and N1. EUS and EUS/fine-needle aspiration are excellent at this
identification.
As to the application of thoracoscopy, I think thoracoscopy and
laparoscopy should be reserved for those patients in whom clinical
stage is not obtainable by EUS or is in doubt. That is very few
patients. Therefore, I would suggest that we stage all our patients
with EUS and EUS/fine-needle aspiration and reserve invasive
staging for those patients who have particular clinical problems.
The question about whether we know that our patients have not
responded to induction therapy (ie, they have persistent N1 or T3
disease) is interesting. I think it is something we now have to
address: What are we going to do with our patients who have
induction therapy and persistent disease? Indeed, those patients
probably should not proceed to resection.
I think that the staging system is a great advance that has
allowed us to understand this disease, but it is imperfect. As we
know, staging is an ongoing process. It is constantly evolving, and
there is a definite possibility that molecular substaging will be
added to it.
Appendix TABLE 2. Multivariable correlates of the magni-
tude of change in T with induction therapy
Variable Estimate  SE* Odds ratio P value
Higher cT 1.8 0.41 0.16† .001
cN1/pN0 0.32 0.45 0.73 .5
SQ cell type 0.1 0.41 0.45 .05
cN1/pN1 2.2 0.53 8.8 .001
cN0/pN1 1.9 0.72 6.9 .007
Intercept 1 0.98 1.11 — .4
Intercept 2 4.7 1.20 — .001
Intercept 3 5.6 1.22 — .001
Intercept 4 6.7 1.26 — .001
SQ, Squamous.
*A negative sign on the coefficient and an odds ratio of less than 1
indicates that the factor is associated with pT cT.
†For each level by which pT cT.
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